FDA nod to first-ever treatment for deadly post-transplant complication TA-TMA
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale
ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium
The Toumai platform, currently the only robotic system with US FDA Study Approval for telesurgery, enabled real-time surgical control with no compromise to patient safety
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
Masitinib targets mast cells, which play a critical role in severe forms of SCD and its complications, including vaso-occlusive crises, acute chest syndrome, and pain
The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies
Afrezza comes in single-use cartridges, delivered via a simple inhaler device. Users select the appropriate cartridge, load it, inhale the insulin, and remove the cartridge
Subscribe To Our Newsletter & Stay Updated